Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459744 | 0.86 | — | — | |
| SCHEMBL21104938 | 0.82 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2HSD17B10KDM4EMAPT | |
| SCHEMBL19815496 | 0.80 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HSD17B10KDM4EMEN1 | |
| SCHEMBL21338976 | 0.77 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4ETSHRLMNA | |
| SCHEMBL805212 | 0.76 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2HSD17B10KDM4EMEN1 | |
| SCHEMBL20284513 | 0.76 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HSD17B10KDM4EMEN1 | |
| SCHEMBL18924943 | 0.76 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HSD17B10KDM4EMEN1 | |
| SCHEMBL2880648 | 0.76 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HSD17B10KDM4EMEN1 | |
| SCHEMBL10149789 | 0.76 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HSD17B10KDM4EMEN1 | |
| SCHEMBL2878783 | 0.76 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2HSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20030143729-A1 | DNA encoding taurine and GABA transporters and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6225115-B1 | DNA encoding taurine and GABA transporters and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| EP-0678028-A4 | DNA ENCODING A HUMAN BETAINE/GABA TRANSPORTER AND USES THEREOF. | SYNAPTIC PHARMA CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5766848-A | RECEPTOR BINDING ASSAY TO DETECT COMPOUND BOUND TO BETAINE/G-AMINOBUTYRIC ACID TRANSPORTER EXPRESSED ON SURFACE OF NONNEURONAL CELLS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5712148-A | GAMMA-AMINOBUTYRIC ACID, VECTORS, PLASMIDS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| US-5658786-A | ISOLATED NUCLEIC ACID | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0631623-A4 | DNA ENCODING TAURINE AND GABA TRANSPORTERS AND USES THEREOF. | SYNAPTIC PHARMA CORP (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996004790-A1 | DNA ENCODING A HUMAN BETAINE/GABA TRANSPORTER AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-22 | — | — | WO | disclosed |
| EP-0678028-A1 | DNA ENCODING A HUMAN BETAINE/GABA TRANSPORTER AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0631623-A1 | DNA ENCODING TAURINE AND GABA TRANSPORTERS AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-01-04 | — | — | EP | disclosed |
| WO-1994015618-A1 | DNA ENCODING A HUMAN BETAINE/GABA TRANSPORTER AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993018143-A1 | DNA ENCODING TAURINE AND GABA TRANSPORTERS AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | ALDH1A1 2210/4885SMN1; SMN2 2139/4885HSD17B10 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.